#2.4b

[perfectbansheenebula]

Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition

There are two FDA-approved medications for the metabolic disorder known as MASH. Roche is paying $2.4 billion to acquire 89bio and its late-stage MASH drug, giving the Swiss pharmaceutical giant the chance to bring a third medication and a different mechanism of action to this prevalent fatty liver disease. According to deal terms announced Thursday, Roche will pay $14.50 for all outstanding…

Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition

[newstech24]

Qualcomm to amass semiconductor agency Alphawave Semi for $2.4B

Qualcomm has agreed to amass Alphawave Semi, a U.Ok.-based semiconductor firm centered on high-speed information middle connectivity, for round $2.4 billion. In keeping with Qualcomm CEO Cristiano Amon, the deal will assist Qualcomm develop its information middle enterprise. “The mixed groups share the objective of constructing superior know-how options and enabling next-level related computing…

Qualcomm to amass semiconductor agency Alphawave Semi for $2.4B